Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Senate committee hears experts urging New Hampshire to schedule xylazine amid rising detections
Summary
The Senate Judiciary Committee heard testimony urging SB 465 to classify xylazine as a Schedule 3 controlled substance, citing toxicology data and concerns that the drug—often combined with fentanyl—blunts naloxone’s effect and causes severe wounds; veterinarians and farm interests requested a carve‑out for legitimate animal use.
Senator Bill Gannon introduced SB 465, a bill to add xylazine — a veterinary tranquilizer increasingly found mixed with illicit opioids — to New Hampshire's state controlled substances schedules and to permit regulated veterinary use.
Kaylee McGlynn, who described her academic research and DEA internship experience, told the committee that state toxicology and federal indicators show xylazine increasingly contaminates the illicit opioid supply. "The DEA has stated that the emergence of Xylazine in The United States is following the same geographical path as fentanyl," she…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
